Such approaches are encouraged by the known but still underexplored responsiveness of MPN cells to HDACi,2,12 and a recent clinical trial that corroborated the safety of HDAC inhibition in patients suffering from leukemia. This evidence concerns the gene HDAC9 and myeloproliferative neoplasm.